Study of Let-7a and miRNA-124 in Cases of Non-Hodgkin's Lymphoma and Acute Leukemia

Sohag University

Status: Not yet enrolling

Conditions: Non Hodgkin Lymphoma and Acute Leukemia

Treatments: Diagnostic Test: real time pcr

Study type: Interventional

Funder types: Other

Identifiers

NCT05477667

Soh-Med-22-7-22

Details and patient eligibility

About

MiRNAs are noncoding RNAs (ncRNAs) that drive post-transcriptional negative regulation of gene expression by promoting the degradation or translational blockade of their target mRNAs. MiRNAs are 21-24-nucleotide-long RNA molecules that are processed from longer RNA precursors (pri-miRNAs) , and either the 5' or the 3' strand of the mature miRNA duplex is loaded into the Argonaute (AGO) family of proteins to form a miRNA-induced silencing complex (miRISC) When bound to AGO proteins, mature miRNAs destabilize or inhibit the translation of partially complementary target mRNAsMiRNA-124 has been shown to be a tumor suppressor, and a decrease in its expression level is typical of tumors of various localization, but there is no evidence of the role of miRNA-124 in the development of NHL . There are a number of studies reflecting the involvement of miRNA-124 in hematopoiesis. Liu et al. showed that miRNA-124 regulates Tip110 that is involved in the differentiation of hematopoietic stem cellsThe let-7 family has been shown to influence the pathogenesis of a variety of hematological malignancies through the changing expression of a number of oncogenic pathways, particularly those related with MYC and that might affect hematopoietic carcinogenesis through the modulation of inflammatory pathways

Enrollment: 100 estimated patients

Sex: All

Ages: 1 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• approval to sign an informed written consent,
• patient with NHL and acute leukemia .

Exclusion criteria

• Refusal to sign an informed written consent,
• patient on chemotherapy

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

100 participants in 3 patient groups

control group

Active Comparator group

Description:

the patients with non-malignant hematological diseases

Treatment:

Diagnostic Test: real time pcr

the cases (A)

Active Comparator group

Description:

NHL .

Treatment:

Diagnostic Test: real time pcr

the cases (B)

Active Comparator group

Description:

acute leukemia

Treatment:

Diagnostic Test: real time pcr